EVMNEvommune, Inc.同业对比
Evommune, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVMN本股 | $362M#7 | 1.8x#1 | 1.3x#5 | 27.9x#4 | 85.7%#1 | -3.1%#7 | -623.6%#4 | -24.8%#3 | — | — | — | — |
| RZLT | $402M#1 | — | 3.4x#11 | — | — | -8.7%#8 | — | -63.7%#10 | -72.2%#2 | — | — | — |
| TTRX | $395M#2 | — | 575.0x#14 | — | — | -80.6%#14 | — | -465.0%#14 | — | — | — | — |
| BBOT | $391M#3 | — | 1.2x#4 | — | — | -80.5%#13 | — | -41.5%#7 | — | — | — | — |
| BNTC | $389M#4 | — | 2.2x#7 | — | -100.0%#5 | -20.1%#9 | — | -25.7%#5 | — | — | -17.9%#3 | — |
| RCKT | $375M#5 | — | 1.0x#2 | — | — | 13.8%#6 | — | -60.5%#9 | — | — | — | — |
| GALT | $374M#6 | — | — | — | — | 34.5%#3 | — | — | — | — | — | — |
| PRLD | $361M#8 | — | 2.7x#9 | 29.7x#5 | 73.4%#2 | 21.8%#5 | -861.3%#5 | -74.4%#11 | — | — | 303.6%#1 | — |
| ENTA | $358M#9 | — | 3.5x#12 | 5.5x#2 | -3.4%#3 | 29.4%#4 | -130.7%#3 | -81.0%#12 | — | — | — | — |
| DMAC | $350M#10 | — | 9.1x#13 | 700.0x#7 | — | -34.0%#11 | -6879.4%#7 | -85.5%#13 | — | — | -7.9%#2 | — |
| QTTB | $333M#11 | 3.6x#2 | 3.1x#10 | 6.2x#3 | — | 162.5%#1 | 31.5%#1 | 28.1%#1 | — | — | — | — |
| EBS | $327M#12 | — | 1.0x#1 | 0.4x#1 | -28.8%#4 | 127.6%#2 | 13.5%#2 | 15.4%#2 | 8.1%#1 | 6#1 | — | — |
| CTNM | $319M#13 | — | 1.3x#6 | — | -100.0%#5 | -41.9%#12 | — | -25.0%#4 | — | — | — | — |
| ABEO | $313M#14 | — | 2.4x#8 | 53.8x#6 | — | -211.7%#15 | -1536.9%#6 | -55.6%#8 | -121.6%#3 | — | — | — |
| SION | $311M#15 | — | 1.2x#3 | — | — | -22.0%#10 | — | -28.3%#6 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议